Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease – a SONIC post hoc analysis von Colombel, J.‐F., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rutgeerts, P., Tang, K. L., Oortwijn, A., Bevelander, G. S., Cornillie, F. J., Sandborn, W. J.

Volltext

Challenges and Opportunities in IBD Clinical Trial Design von Dubinsky, Marla C., Collins, Rory, Abreu, Maria T., Abreu, Maria T., Collins, Rory, Dubinsky, Marla C., Jairath, Vipul, Lewis, James D., Lindsay, James, Merad, Miriam, Ng, Siew, Panaccione, Remo, Panes, Julian, Sands, Bruce, Siegal, Corey A., Singh, Siddarth, Vermeire, Severine, Ahuja, Vineet, Allez, Matthieu, Ananthakrishnan, Ashwin, Bemelman, Willem, Braun, Jonathan, Colombel, Jean-Frederic, Danese, Silvio, D’Haens, Geert, D’Hoore, André, Dignass, Axel, Dotan, Iris, Gassul, Miguel Angel, Griffiths, Anne, Halfvarson, Jonas, Hanauer, Stephen, Kotze, Paulo, Koutroubakis, Ioannis, Loftus, Edward, Louis, Edouard, Magro, Fernando, Mantzaris, Gerassimos, Mary, Jean-Yves, McGovern, Dermot, Munkholm, Pia, O’Morain, Colm, Panis, Yves, Peyrin-Biroulet, Laurent, Prantera, Cosimo, Ran, Zhihua, Siegmund, Britta, Silverberg, Mark, Stange, Eduard, Targan, Stephan, Tysk, Curt, Travis, Simon, Vatn, Morton, Yamamoto-Furusho, Yesus, Aarts, Janske, Abhyankar, Brihad, Ahmad, Harris, Aranda, Richard, Arora, Vipin, Benjacoub, Jalil, Berg, Sofie, Besuyen, Robin, Bojic, Daniela, Carriero, Valerio, Cataldi, Fabio, D’Agay, Laurence, Delgado-Aros, Silvia, Giannasca, Paul, Goyal, Kavitha, Greinwald, Roland, Gropper, Savion, Kageyama, Shunsuke, Laoun, Raphaël, Levesque, Barrett, Lissoos, Trevor, Modesto, Irene, Mohrbacher, Ralf, Mueller, Ralph, Naegeli, April, Naik, Snehal, Nguyen, Deanne, Niezychowski, Wojciech, O’Brien, Caitriona, Odnoletkova, Irina, Oortwijn, Alessandra, Park, Kun K.T., Radziszewski, Waldemar, Salese, Leonardo, Spleiss, Johannes, Stancati, Andrea, Tatro, Amanda, Thompson, Jennifer, Hofmann, Robert, Zambrano, Javier, Zhou, Wen, Zigmont, Ellen

Volltext

P319 Characteristics of filgotinib-treated patients with Ulcerative Colitis who achieve sustained corticosteroid-free remission: Post hoc analysis of the phase 2b/3 SELECTION study von Kobayashi, T, Dignass, A, Roblin, X, Fujitani, Y, Oortwijn, A, Jamoul, C, Hibi, T

Volltext

P772 Comprehensive disease control in patients with Ulcerative Colitis: refinement of a multi-component endpoint using data from the filgotinib SELECTION trial von Schreiber, S W, Feagan, B G, Vermeire, S, Danese, S, Vyncke, V, Faes, M, Oortwijn, A, Peyrin-Biroulet, L

Volltext

P517 Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies von Vermeire, S, Feagan, B, Peyrin-Biroulet, L, Oortwijn, A, Faes, M, de Haas, A, Rogler, G

Volltext

DOP45 Predicting late responders to filgotinib in patients with moderately to severely active Ulcerative Colitis: A post hoc analysis of SELECTION and SELECTIONLTE von Matsuoka, K, Löwenberg, M, Fumery, M, Takatori, Y, Fujitani, Y, Oortwijn, A, Faes, M, Jamoul, C, Hibi, T

Volltext

OP35 Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200 mg among patients with Ulcerative Colitis: Results from the SELECTIONLTE study von Feagan, B G, Matsuoka, K, Rogler, G, Faes, M, Oortwijn, A, de Haas, A, Rudolph, C, Peyrin-Biroulet, L

Volltext

P690 Prolonged benefit of filgotinib in patients with Ulcerative Colitis in SELECTION von Laharie, D, Sturm, A, Kobayashi, T, Matsumoto, T, Oortwijn, A, Jamoul, C, Faes, M, de Haas, A, Vermeire, S

Volltext

P736 Factors associated with partial Mayo Clinic Score over time in patients with Ulcerative Colitis treated with filgotinib in the phase 2b/3 SELECTION trial von Peyrin-Biroulet, L, Louis, E, Hisamatsu, T, Jamoul, C, Santermans, E, Harris, K, de Haas, A, Oortwijn, A, Feagan, B

Volltext

P393 Effect of filgotinib on anaemia in patients with Ulcerative Colitis in SELECTION von Loveikyte, R, de Haas, A, Oortwijn, A, Eskens, B, Jamoul, C, Muller, K, van der Meulen-de Jong, A

Volltext

P225 Mucosal transcriptomic profiles associated with clinical response in patients with Ulcerative Colitis receiving filgotinib von Magro, F, Feagan, B G, Rogler, G, Peyrin-Biroulet, L, Bauer, Y, Cougnaud, L, Oortwijn, A, Randall, M, Rudolph, C, Reinisch, W

Volltext

P551 Benefit–risk trade-offs and patient preferences for therapy selection in Ulcerative Colitis: a multi-country preference study von Gisbert, J P, Schreiber, S, Siegel, C A, Magro, F, Jus, A, Whichello, C, Michaels-Igbokwe, C, Heidenreich, S, Oortwijn, A, Vermeire, S

Volltext

P293 Insights from patients with Ulcerative Colitis on disease burden: Findings from a real-world survey in Europe von Burisch PhD, J, Hart, A, Oortwijn, A, Khalid, J M, Hennessy, F, Knight, H, Meadows, R, Patel, H, Armuzzi, A

Volltext

DOP37 Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies von Schreiber, S, Loftus, E V, Maaser, C, Danese, S, Rudolph, C, Jongen, R, De Haas, A, Oortwijn, A, Vermeire, S

Volltext

POSA350 Effect of Filgotinib on EQ-5D-5L and Work Productivity and Activity Impairment Among Patients with Ulcerative Colitis: Results from the Phase 2B/3 Selection Trial von Danese, S, Feagan, B, Schreiber, S, Vermeire, S, Harris, K, Hasegawa, K, L.U., X, Oortwijn, A, Patel, H, Sandborn, W, Peyrin-Biroulet, L

Volltext

P624 Investigating the symptom burden among European patients with moderate-to-severe Crohn’s disease using a real-world survey von Burisch, J, Hart, A, Sturm, A, Knight, H, Rudolph, C, Meadows, R, Oortwijn, A, Weatherby, S, Rolph, R, Dawod, F, Armuzzi, A

Volltext

OP25 Efficacy of filgotinib in patients with Ulcerative Colitis by line of therapy in the phase 2b/3 SELECTION trial von Peyrin-Biroulet, L, Dotan, I, Hibi, T, Taliadouros, V, Oortwijn, A, Zhao, S, Zhang, J, Hsieh, J, Feagan, B

Volltext

What principles should govern the use of managed entry agreements? von Klemp, Marianne, Frønsdal, Katrine B., Facey, Karen

Volltext

OP07 Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treate... von Schreiber, S, Feagan, B, Peyrin-Biroulet, L, Vermeire, S, Faes, M, Harris, K, Oortwijn, A, Daniele, P, Patel, H, Danese, S

Volltext

P491 Efficacy and safety outcomes of long-term treatment with filgotinib 200 mg among patients with Ulcerative Colitis: An interim analysis of SELECTIONLTE von Feagan Senior Scientific Officer, B G, Matsuoka, K, Rogler, G, Faes, M, Oortwijn, A, de Haas, A, Rudolph, C, Patel, H, Peyrin-Biroulet, L

Volltext